OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer With EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA10.05 an Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients With Uncommon EGFR Mutation(KCSG-Lu15-09)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC With Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated With Chemotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies

Cancer
Cancer ResearchOncology
2018English

Icotinib in Patients With Pretreated Advanced Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy